BioVie (BIVI) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
15 Jan, 2026Opening remarks and agenda
Meeting called to order by the Chairman, with board members and key executives attending virtually.
Independent public accountants and outside securities counsel were present.
Secretary appointed to record minutes and report on formal meeting steps.
Corporate governance
Record date for voting set as September 30, 2024, with 7,956,660 shares outstanding.
Notice of meeting, proxy statement, and annual report mailed to shareholders on October 9, 2024.
Each share entitled to one vote; quorum confirmed with 60.8% of shares represented.
Board and executive committee updates
Six directors nominated and elected for a one-year term: Jim Lang, Cuong Do, Michael Sherman, Richard Berman, Robert Hariri, and Sigmund Rogich.
Partial view of Summaries dataset, powered by Quartr API
Latest events from BioVie
- Net loss widened to $5.3M for the quarter as R&D spending rose, with cash at $13.1M.BIVI
Q3 202611 May 2026 - Bezisterim targets neuroinflammation and metabolic dysfunction, aiming to improve Parkinson's outcomes.BIVI
KOL event7 May 2026 - Lead therapies show strong efficacy in neurodegeneration and ascites, with high commercial potential.BIVI
Corporate presentation23 Apr 2026 - Imminent clinical data for Parkinson's and long COVID could unlock major market opportunities.BIVI
Biotech Resurgence: Platforms and Pipelines of Today's Innovators16 Apr 2026 - Phase II data for Parkinson's and long COVID expected in 2024; BIV201 phase III planning underway.BIVI
Status update4 Mar 2026 - Net loss narrowed, cash bolstered by $10.5M raise, but going concern risks persist.BIVI
Q2 20266 Feb 2026 - Directors elected, auditor ratified, and equity plan amendment approved by strong majority.BIVI
AGM 20253 Feb 2026 - Key clinical trials advance with strong cash runway and major data readouts expected by mid-2026.BIVI
Investor Update29 Dec 2025 - Shareholders will vote on director elections, auditor ratification, say-on-pay, and a major equity plan increase.BIVI
Proxy Filing2 Dec 2025